Dongdong Luo, Xingyang Qiu, Qingquan Zheng, Yue Ming, Wencheng Pu, Ming Ai, Jianhua He and Yong Peng*,
{"title":"发现治疗癌症的新型受体酪氨酸激酶样孤儿受体 1 (ROR1) 抑制剂","authors":"Dongdong Luo, Xingyang Qiu, Qingquan Zheng, Yue Ming, Wencheng Pu, Ming Ai, Jianhua He and Yong Peng*, ","doi":"10.1021/acs.jmedchem.4c00175","DOIUrl":null,"url":null,"abstract":"<p >Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncogenic membrane protein in several malignancies and has been considered an attractive target for the treatment of human cancers. In this study, structure-based virtual screening and structure optimization were conducted to identify novel ROR1 inhibitors. Based on hit compound <b>2</b>, 45 novel ROR1 inhibitors were designed and synthesized, and the detailed structure–activity relationship was investigated. Representative compound <b>19h</b> potently binds ROR1 with a <i>K</i><sub>D</sub> value of 0.10 μM, exhibiting antitumor activity in lung cancer and breast cancer cell lines (IC<sub>50</sub>: 0.36–1.37 μM). Additionally, a mechanism investigation demonstrated that compound <b>19h</b> induces the apoptosis of tumor cells. Importantly, compound <b>19h</b> significantly suppressed tumor growth in a mouse model without obvious toxicity. Overall, this work identified compound <b>19h</b> as a new ROR1 inhibitor, providing a novel lead compound for the treatment of lung cancer and breast cancer.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"67 13","pages":"10655–10686"},"PeriodicalIF":6.8000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment\",\"authors\":\"Dongdong Luo, Xingyang Qiu, Qingquan Zheng, Yue Ming, Wencheng Pu, Ming Ai, Jianhua He and Yong Peng*, \",\"doi\":\"10.1021/acs.jmedchem.4c00175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncogenic membrane protein in several malignancies and has been considered an attractive target for the treatment of human cancers. In this study, structure-based virtual screening and structure optimization were conducted to identify novel ROR1 inhibitors. Based on hit compound <b>2</b>, 45 novel ROR1 inhibitors were designed and synthesized, and the detailed structure–activity relationship was investigated. Representative compound <b>19h</b> potently binds ROR1 with a <i>K</i><sub>D</sub> value of 0.10 μM, exhibiting antitumor activity in lung cancer and breast cancer cell lines (IC<sub>50</sub>: 0.36–1.37 μM). Additionally, a mechanism investigation demonstrated that compound <b>19h</b> induces the apoptosis of tumor cells. Importantly, compound <b>19h</b> significantly suppressed tumor growth in a mouse model without obvious toxicity. Overall, this work identified compound <b>19h</b> as a new ROR1 inhibitor, providing a novel lead compound for the treatment of lung cancer and breast cancer.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"67 13\",\"pages\":\"10655–10686\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00175\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00175","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncogenic membrane protein in several malignancies and has been considered an attractive target for the treatment of human cancers. In this study, structure-based virtual screening and structure optimization were conducted to identify novel ROR1 inhibitors. Based on hit compound 2, 45 novel ROR1 inhibitors were designed and synthesized, and the detailed structure–activity relationship was investigated. Representative compound 19h potently binds ROR1 with a KD value of 0.10 μM, exhibiting antitumor activity in lung cancer and breast cancer cell lines (IC50: 0.36–1.37 μM). Additionally, a mechanism investigation demonstrated that compound 19h induces the apoptosis of tumor cells. Importantly, compound 19h significantly suppressed tumor growth in a mouse model without obvious toxicity. Overall, this work identified compound 19h as a new ROR1 inhibitor, providing a novel lead compound for the treatment of lung cancer and breast cancer.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.